These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12694528)

  • 41. Disseminated intravascular coagulation in a patient with haemophilia B during factor IX replacement therapy.
    Ohga S; Saito M; Matsukazi A; Kai T; Ueda K
    Br J Haematol; 1993 Jun; 84(2):343-5. PubMed ID: 8398841
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune tolerance therapy dose as an outcome predictor.
    DiMichele D
    Haemophilia; 2003 Jul; 9(4):382-6. PubMed ID: 12828672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of OCTANINE F in children with haemophilia B.
    Klukowska A; Laguna P; Svirin P; Shiller E; Vdovin V
    Haemophilia; 2008 May; 14(3):531-8. PubMed ID: 18355266
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.
    Kavakli K; Smith L; Kuliczkowski K; Korth-Bradley J; You CW; Fuiman J; Zupančić-Šalek S; Abdul Karim F; Rendo P
    Haemophilia; 2016 May; 22(3):381-8. PubMed ID: 26823276
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Disappearance of inhibitor to factor IX in a patient with severe haemophilia B and immunological characterization of the inhibitor.
    Ohkubo Y; Takahashi Y; Sugimoto M; Nishino M; Nishimura T; Yoshioka A; Fukui H
    Clin Lab Haematol; 1988; 10(2):177-85. PubMed ID: 2843318
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
    Collins PW; Quon DVK; Makris M; Chowdary P; Kempton CL; Apte SJ; Ramanan MV; Hay CRM; Drobic B; Hua Y; Babinchak TJ; Gomperts ED
    Haemophilia; 2018 Jan; 24(1):104-112. PubMed ID: 28833808
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prophylaxis in patients with haemophilia complicated by inhibitors].
    Paweł Ł
    Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Immune tolerance induction in a case of hemophilia B with inhibitor with prothrombin complex concentrate and rituximab].
    Xue F; Liu W; Cheng YF; Liu XF; Huang YT; Fu RF; Zhang L; Yang RC
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):749-753. PubMed ID: 29081190
    [No Abstract]   [Full Text] [Related]  

  • 50. Evaluation of the safety and efficacy of recombinant factor IX (nonacog alfa) in minimally treated and previously treated Chinese patients with haemophilia B.
    Yang R; Zhao Y; Wang X; Sun J; Jin J; Wu D; Charnigo R; O'Brien A; Zhong Z; Rendo P
    Haemophilia; 2012 Sep; 18(5):e374-8. PubMed ID: 22776196
    [No Abstract]   [Full Text] [Related]  

  • 51. Immune tolerance induction and the treatment of hemophilia. Malmö protocol update.
    Berntorp E; Astermark J; Carlborg E
    Haematologica; 2000 Oct; 85(10 Suppl):48-50; discussion 50-1. PubMed ID: 11187871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B.
    Saini S; Croteau SE; Horling FM; Dunn AL
    Haemophilia; 2019 Mar; 25(2):e126-e129. PubMed ID: 30817051
    [No Abstract]   [Full Text] [Related]  

  • 53. Challenges in the management of hemophilia B with inhibitor.
    Batorova A; Morongova A; Tagariello G; Jankovicova D; Prigancova T; Horakova J
    Semin Thromb Hemost; 2013 Oct; 39(7):767-71. PubMed ID: 24022802
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B.
    Recht M; Pollmann H; Tagliaferri A; Musso R; Janco R; Neuman WR
    Haemophilia; 2011 May; 17(3):494-9. PubMed ID: 21518148
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
    Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
    Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
    [No Abstract]   [Full Text] [Related]  

  • 56. Inhibitor incidence in previously untreated patients with severe haemophilia B: a systematic literature review.
    Franchini M; Santoro C; Coppola A
    Thromb Haemost; 2016 Jul; 116(1):201-3. PubMed ID: 27052668
    [No Abstract]   [Full Text] [Related]  

  • 57. Inhibitor eradication with rituximab in haemophilia: where do we stand?
    Franchini M; Mannucci PM
    Br J Haematol; 2014 Jun; 165(5):600-8. PubMed ID: 24628543
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful treatment of immune tolerance induction with rituximab in a patient with severe hemophilia B and inhibitor.
    Kobayashi R; Sano H; Suzuki D; Kishimoto K; Yasuda K; Honjo R; Hirose M; Fujita S; Abe S; Kobayashi K
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):580-2. PubMed ID: 25811452
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune tolerance in haemophilia: the long journey to the fork in the road.
    DiMichele DM
    Br J Haematol; 2012 Oct; 159(2):123-34. PubMed ID: 22924753
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery.
    Ragni MV; Pasi KJ; White GC; Giangrande PL; Courter SG; Tubridy KL;
    Haemophilia; 2002 Mar; 8(2):91-7. PubMed ID: 11952843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.